Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
McKesson
Dow
Boehringer Ingelheim
AstraZeneca
Express Scripts

Last Updated: December 2, 2021

DrugPatentWatch Database Preview

Patent: 6,033,665

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 6,033,665
Title: Compositions and methods for modulating leukocyte adhesion to brain endothelial cells
Abstract:The invention is directed to compositions and methods for modulating the adhesion of leukocytes to brain endothelial cells. More specifically, the present invention relates to the use of reagents to inhibit the binding of VLA-4 leukocyte cell surface receptors to brain endothelial adhesion molecules. Also provided are compositions and methods for treating brain inflammation. A method of inducing brain inflammation as well as an assay for testing anti-inflammatory agents is also provided.
Inventor(s): Yednock; Theodore A. (Fairfax, CA)
Assignee: Elan Pharmaceuticals, Inc. (South San Francisco, CA)
Application Number:08/457,847
Patent Claims:see list of patent claims

Details for Patent 6,033,665

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Biogen Inc. TYSABRI natalizumab Injection 125104 2004-11-23 ⤷  Free Forever Trial 2017-03-07
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

International Patent Family for US Patent 6,033,665

Country Patent Number Estimated Expiration
World Intellectual Property Organization (WIPO) 9105038 ⤷  Free Forever Trial
United States of America 5260210 ⤷  Free Forever Trial
Japan H05503920 ⤷  Free Forever Trial
Japan 3308526 ⤷  Free Forever Trial
Japan 2002284700 ⤷  Free Forever Trial
European Patent Office 0493444 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Colorcon
AstraZeneca
Mallinckrodt
Johnson and Johnson
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.